Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab and Nivolumab in Advanced NSCLC
NCT02947386Phase 1Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2017
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nimotuzumab in non-small cell lung cancer (NSCLC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Dose-Limiting Toxicities at 28 days and Overall Response Rate at 3 years. Started Jun 2017; status: completed.
02
Drugs
nimotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02947386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947386.